CSF2 and breast cancer: Using CM derived from GM-CSF-deficient 4T1 cells to treat macrophages resulted in impaired STAT5 phosphorylation (Fig. 5c and Supplementary Fig. S7a), indicating the reliance of breast cancer cells on GM-CSF to promote STAT5 activation in macrophages.